23
Views
1
CrossRef citations to date
0
Altmetric
Miscellaneous

Aerothricins: a new class of β-glucan inhibitors

Pages 315-318 | Published online: 25 Feb 2005

Bibliography

  • GEORGOPAPADAKOU NF: Update on antifungals targeted to the cell wall: focus on 3-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10(2):269–280.
  • •Good, recent review on antifungals and the P-glucan inhibitors.
  • MASUBUCHI K, OKADA T, KOHCHI M etal.: Synthesis and antifungal activities of novel 1,3-13-D-glucan synthase inhibitors. Part 1. Bioorg. Med. Chem. Lett. (2001) 11:395–398.
  • ••Contains much of the information, and compound information used in the generation of the reviewed patents.
  • MASUBUCHI K, OKADA T, KOHCHI M et al: Synthesis and antifungal activities of novel 1,3-13-D-glucan synthase inhibitors. Part 2. Bioorg. Med. Chem. Lett. (2001) 11:1273–1276.
  • ••Contains much of the information, and compound information used in the generation of the reviewed patents.
  • TSUKUDA T et al.: Modeling, synthesis and biological activity of novel antifungal agents. Bioorg. Med. Chem. Lett. (1998) 8:1819–1824.
  • ••Excellent SAR approach to thehexapeptides.
  • HECTOR RF: Compounds active against cell walls of medically important fungi. Clin. Microbial. Rev (1993) 6(1):1–21.
  • •Review article on antifungal compounds targeting the cell wall.
  • KRISHNARAO TV, GALGIANI JN: of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41:1957–1960.
  • BARCHIESI F, SCHIMIZZI AM, FOTHERGILL AW, SCALISE G, RINALDI MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. j Clin. Microbial. Infect. Dis. (1999) 18:302–304.
  • MOORE CB, OAKLEY KL, DENNING DW In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. 11/licrobioL Infect. (2001) 7:11–16.
  • MIKAMO H, SATO Y, TAMAYA T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. j Antimicrob. Chemother. (2000) 46:485–487.
  • ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. j Gun. Microbial. (1998) 36:2950–2956.
  • •Good comparative in vitro study of the two leading echinocandirts and one of the newer azoles versus a wide variety of medically important yeast, dimorphics and filamentous fungi.
  • PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbial. Infect. Dis. (1998) 30:251–255.
  • •Good in vitro study of the echirtocandins against a wide variety of filamentous fungi.
  • GRAYBILL JR:. Changing strategies for treatment of systemic mycoses. Biz. Infect. Dis. (2000) 4(2):47–54.
  • STEVENS DA: Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob. Agents Chemother. (2000) 44:2547–2548.
  • ••This paper describes the rather dramatic seen with the combination of [3-glucan and chitin synthase inhibitors.
  • GANESAN LT, MANAVATHU EK, CUTRIGHT JL, CHANDRASEKAR PH: In vitro synergy of a combination of nikkomycin plus echinocandin against Aspergillus fumigatus. Abstract 649, 39th Annual Meeting of the Infectious Disease Society of America.
  • CHIOU CC, MAVROGIORGOS N, TILLEM E, HECTOR R, WALSH TJ. Synergy, pharmacodynamics, and time-sequenced ultrastrctural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemo. (2001) 45:3310–3321.
  • ••Paper describing the rather dramaticsynergy seen with the combination of [3-glucan and chitin synthase inhibitors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.